InvestorsHub Logo
Followers 61
Posts 3376
Boards Moderated 1
Alias Born 12/26/2012

Re: blackhawks post# 50511

Saturday, 01/26/2013 10:06:05 PM

Saturday, January 26, 2013 10:06:05 PM

Post# of 130503
The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson’s Research. The Company also owns an inventory of 88 cell lines referred to as “PhenoGuard Cell Lines.” MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System will be identified from the Company’s inventory of PhenoGuard Cell Lines.

Source: http://ih.advfn.com/p.php?pid=nmona&article=49757501